Moderna, Inc.

As of June 30, 2026, Moderna, Inc. carries a market capitalization of 18.83B, placing it among publicly traded companies globally. Its enterprise value stands at 14.98B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Moderna, Inc.'s next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Moderna, Inc. has 399.00M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 8.41, and the price-to-book ratio stands at 2.79.

These figures are as of June 30, 2026. The EV/Sales ratio of 6.78 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 14.98B versus a market cap of 18.83B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Moderna, Inc. maintains a current ratio of 2.29, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.04, indicating elevated leverage, while an interest coverage ratio of -73.31 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Moderna, Inc. posted a negative return on equity (ROE) of -39.00, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -27.43, reflecting losses generated across the asset base. The company generates approximately 444,221.11 in revenue per employee across its workforce of 4,975.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.57 indicates how many times Moderna, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Moderna, Inc. recorded 64.00M in income tax expense. The company reported a pretax loss of -3.09B and -3.15B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

These figures are as of the close on October 20, 2026.

Over the twelve months ended June 30, 2026, Moderna, Inc. generated 2.21B in revenue and converted that into -3.15B in net income, yielding earnings per share of -8.00. EBITDA reached -3.08B, while operating income came in at -3.32B.

As of June 30, 2026, Moderna, Inc. holds 5.14B in cash and equivalents against 1.29B in total debt, resulting in a net debt position of -1.13B. Total book value stands at 6.76B, with working capital of 3.28B providing operational flexibility.

Moderna, Inc. produced -1.07B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -171.00M in capital expenditures, free cash flow totaled -1.24B - equivalent to -3.16 per share.

Over the twelve months ended June 30, 2026, Moderna, Inc. posted a gross margin of 22.76, reflecting its pricing power and cost economics. The operating margin of -150.23 and net profit margin of -142.58 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -6.69: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -3.24, meaning Moderna, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Moderna, Inc. has an Altman Z-Score of 2.91, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.